指南与共识真菌感染

英国医学真菌学会2025年严重真菌病诊断最佳实践建议更新

British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update.
指南 / 共识 · Lancet Infect Dis · 2025-11-10

英国医学真菌学会召集专家组更新2015年最佳实践指南,针对严重真菌病诊断,基于近期证据提出新增强推荐,包括肺孢子菌PCR、1,3-β-D-葡聚糖检测、高通量呼吸道培养、扩展高危人群曲霉抗原/抗体检测、特定情境念珠菌和毛霉PCR、泛真菌PCR和测序鉴定、以及泊沙康唑和艾沙康唑治疗药物监测。建议以可审核标准呈现,强调诊断与抗真菌药物管理及临床路径整合。

要点

  • 推荐肺孢子菌PCR和1,3-β-D-葡聚糖用于疑似侵袭性念珠菌病和肺孢子菌肺炎。
  • 扩展曲霉抗原/抗体检测至ICU和慢性呼吸病(含哮喘)等临床脆弱人群。
  • 特定情境使用念珠菌PCR和毛霉PCR,泛真菌PCR和测序用于阳性镜检或病理标本鉴定。

核心结论

  • 基于近期证据更新2015年指南,新增或强化多项真菌诊断检测推荐,并以可审核标准促进实施和质量改进。

研究设计与样本

  • 英国医学真菌学会召集专家组制定最佳实践建议,针对严重真菌病诊断,基于近期证据更新2015年指南。

主要发现

  • 组织病理学和影像学检查建议与2015年标准保持一致。
  • 对每种真菌检测提供专项评论和表格,包含从样本采集到报告的预期周转时间。

关键数值与推荐

  • 推荐使用肺孢子菌PCR。
  • 推荐1,3-β-D-葡聚糖检测用于疑似侵袭性念珠菌病和肺孢子菌肺炎。
  • 推荐更高体积的呼吸道样本培养。
  • 推荐在扩展的临床脆弱人群中检测曲霉抗原或抗体,包括ICU患者和慢性呼吸病患者(含哮喘)。
  • 推荐特定情境下使用念珠菌PCR和毛霉PCR,以及泛真菌PCR和DNA测序用于阳性镜检或组织病理标本的真菌鉴定。

临床怎么用

  • 将诊断检测与抗真菌药物管理和临床路径整合,适用于调查多病共存疑似真菌病的临床医生。
  • 建议以可审核标准形式实施,便于质量改进。
  • 虽聚焦成人和英国实践,但讨论了在儿科人群和全球的适用性。

局限性

  • 建议主要基于成人数据且聚焦英国实践,儿科和全球适用性需进一步讨论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The fungal diagnostic landscape is evolving; whereas previously, traditional culture-based methods dominated, most invasive fungal disease is now diagnosed with non-culture-based tests, including direct microscopy, antigen, antibody, and molecular assays, supported by histopathology and radiology. Access to and turnaround time of diagnostic tests and their clinical implementation varies across the UK. The British Society for Medical Mycology convened an expert group to update its 2015 best practice guidance. Guidance on histopathology and radiology investigations remain unchanged from the 2015 standards of care. For each mycological test, we include test-specific commentaries and accompanying tables, with expected turnaround times (sample collection to reporting). Based on recent evidence, new or stronger recommendations include use of Pneumocystis PCR; 1,3-β-D-glucan testing for suspected invasive candidiasis and Pneumocystis pneumonia; higher volume respiratory sample cultures; Aspergillus antigen or antibody-based testing in expanded clinically vulnerable populations, including patients in intensive care units and patients with chronic respiratory disease (including asthma); use of Candida PCR and Mucorales PCR in specific contexts; pan-fungal PCR and DNA sequencing for fungal identification from positive microscopy or histopathology specimens; and inclusion of posaconazole and isavuconazole in therapeutic antifungal monitoring recommendations. We discuss integration of diagnostic tests with antifungal stewardship and common clinical scenarios. Although recommendations focus on adults and UK practice, use in paediatric populations and worldwide applicability is discussed. Recommendations are presented as auditable standards to facilitate implementation and quality improvement measures. An emphasis on integration of combined diagnostics with antifungal stewardship and clinical pathways extends guideline relevance beyond microbiology laboratories to clinicians investigating patients with multimorbidity and suspected fungal disease within increasingly complex health-care systems.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Schelenz S, Abdolrasouli A, Armstrong-James D, et al. British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update. Lancet Infect Dis. 2025. PMID: 41232547. doi:10.1016/S1473-3099(25)00550-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。